2.2 Dementia-Related Psychosis

Early Stage Clinical Programs

M1 PAM Program

Highly selective positive allosteric modulators (PAMs) of the M1 subtype of the muscarinic acetylcholine receptor may represent a novel approach for improving cognitive function and other neuropsychiatric symptoms in patients suffering from CNS disorders. Our M1 program is a portfolio of early-stage candidates and our lead compound is currently in early Phase 1 testing.


There is an urgent need for new approaches to treat pain without causing addiction. ACP-044 is a unique Reactive Species Decomposition Accelerant (RSDAx), a first-in-class, non-opioid mechanism of action focused on interrupting pathways that sensitize neurons to pain. ACP-044 has shown promising efficacy and safety results in animal models evaluating incisional, inflammatory, and neuropathic pain, as well as favorable tolerability and pharmacokinetic properties in Phase 1 trials. Acadia plans to initiate a Phase 2 clinical study in the first half of 2021.

*The safety and efficacy of this investigational agent have not been established or approved by the FDA.